Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11974082 | 0.85 | — | — | |
| SCHEMBL11974086 | 0.85 | — | — | |
| SCHEMBL11974085 | 0.85 | — | — | |
| SCHEMBL13105861 | 0.77 | CHRNB2 (0.32) | TSHRL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL14108542 | 0.77 | SMN1; SMN2 (0.34) | TSHRLMNAHPGDSMN1; SMN2 | |
| SCHEMBL5197245 | 0.76 | TSHR (0.46) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10412699 | 0.74 | TSHR (0.48) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL20502579 | 0.74 | TSHR (0.44) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL21164663 | 0.74 | TSHR (0.44) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL994667 | 0.74 | LMNA (0.44) | TSHRGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| EP-2948447-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2016-09-21 | — | — | EP | disclosed |
| US-20160137634-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-05-19 | — | — | US | disclosed |
| US-20160137634-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-05-19 | — | — | US | disclosed |
| US-9156831-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| US-9156831-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| WO-2014114928-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1058680-B1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | TSHR 2972/4885GABRP 1420/4885GABRD 2387/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | TSHR 3047/4885GABRP 1279/4885GABRD 2022/4885 |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, TP53 | TSHR 1453/4885GABRP 4578/4885GABRD 4799/4885 |
| US-20160137634-A1 | Chemical Compounds | MKI67, CCNI, TP53 | TSHR 1453/4885GABRP 4578/4885GABRD 4799/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | TSHR 3028/4885GABRP 1203/4885GABRD 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.